Creative Diagnostics Introduces CC50/IC50 Assay Services for Pharmaceutical Safety

Creative Diagnostics introduced CC50/IC50 testing services with a high level of detection sensitivity and accuracy. - June 11, 2022 - Creative Diagnostics

Creative Diagnostics Launches Measles Virus Antigens for the Detection of Antibodies

Creative Diagnostics announced the release of new measles virus antigens suitable for both IgM and IgG detection. - June 11, 2022 - Creative Diagnostics

Creative Diagnostics Announces Antigens for Epstein-Barr Virus Antibody Tests

Creative Diagnostics recently launched recombinant antigens p18 and p23 (viral capsid antigens, VCA), p54 and p138 (early antigens, EA) and EBNA1 (nuclear antigen, EBNA). - May 26, 2022 - Creative Diagnostics

Creative Diagnostics Launches Antibody-Dependent Enhancement Assay Services

Creative Diagnostics recently introduces comprehensive services for antibody-dependent enhancement (ADE) assay. - May 26, 2022 - Creative Diagnostics

Molekule Consulting Announces the Launch of E.U. - Based Operations

Molekule Consulting Announces the Launch of E.U. - Based Operations

Molekule Consulting announces the launch of an E.U. - based business / Molekule Hub continuing their focus on the development of global strategy and advisory services for the biopharmaceutical sector. - May 24, 2022 - Molekule Consulting

NuvOx Pharma Announces Issuance of a New Patent

NuvOx Pharma has been issued US Patent No. 11,304,899, entitled “Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof.” - May 19, 2022 - NuvOx Pharma

NuvOx Appoints Dr. Robert King to SAB

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, appointed Dr. Robert King to its Scientific Advisory Board (SAB). Dr. King is a seasoned life science executive with over 30 years’... - May 11, 2022 - NuvOx Pharma

Creative Diagnostics Introduces New Nipah Virus Antigens and Antibodies

Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. - April 30, 2022 - Creative Diagnostics

Microvascular Therapeutics Finalizes Facility Certification for the Production of Its Product, MVT-100

Microvascular Therapeutics (MVT), a clinical stage biotechnology company, finalized its manufacturing facility certifications for the GMP production of its first product, MVT-100. - April 21, 2022 - Microvascular Therapeutics

NuvOx Technology Featured in Prominent Peer Review Journal

NuvOx Pharma’s technology, which is developed as a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, was featured in the prominent journal of Frontiers of Neurology. - April 19, 2022 - NuvOx Pharma

NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, finalized its manufacturing facility certifications for Phase IIb trials. - April 17, 2022 - NuvOx Pharma

Dr. Claudia C. Cotca of C3 Think Tank Appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health

Dr. Claudia C. Cotca of C3 Think Tank appointed as Advisor Chair of Advanced Technology Academic Research Center (ATARC) on Digital AI & Data Analytics Warfighter Health. Together with leadership and military health experts, stakeholders and program officers, Dr. Claudia C Cotca will help support and contribute to the scope and mission of ATARC’s Warfighter Health in incorporating responsibly artificial intelligence in military medicine. - April 13, 2022 - C3 Think Tank

Microvascular Therapeutics Receives Funds from Commercialization Readiness Program for the Development of Its Ultrasound Contrast Agent, MVT-100

MicrovMicrovascular Therapeutics (MVT), a biotechnology company based in Tucson, AZ, was recently awarded a Commercialization Readiness Program grant from the National Institute of Heart, Lung, and Blood Institute (NHLBI). Wyatt Unger, MD, MBA, Chief Medical Officer of MVT said, “We are... - April 09, 2022 - Microvascular Therapeutics

Creative Diagnostics Launches Staphylococcal Enterotoxin Antigens

Creative Diagnostics recently launches a range of natural and recombinant staphylococcal enterotoxin antigens. - March 31, 2022 - Creative Diagnostics

NuvOx Receives Notice from the Breakthrough DOD Award for Its Immuno-Oncology Program

On February 11th, 2022, NuvOx Pharma received notice from the Department of Defense (DOD) office of the Congressionally Directed Medical Research Programs (CDMRP) that the Company has been awarded a grant from the Breast Cancer Research Program Breakthrough Award. The grant would fund a... - March 05, 2022 - NuvOx Pharma

Timothy Healey Joins the Board of Director at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Timothy Healey to the MVT Board of Directors. Mr. Healey bring a global perspective to pharmaceutical launch and commercialization. “I am very pleased and honored... - February 23, 2022 - Microvascular Therapeutics

NuvOx to Participate in the BIO CEO Investor Conference

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in BIO CEO & Investor Conference, held at New York City from February 14 - 17, 2022. The management team will be... - February 11, 2022 - NuvOx Pharma

ImaRx Investments Receives ISO-7 Certification for Its GMP Manufacturing Suite: Both Microvascular Therapeutics and NuvOx Pharma Will Benefit

ImaRx Investments, LLC, an investment firm based in Tucson, Arizona, has received ISO-7 certification on February 1st for its GMP manufacturing suite. The 1,800 square foot, ISO-5 capable clean room is designed for manufacturing injectable drugs. The facility is the only one of its kind in Southern... - February 08, 2022 - Microvascular Therapeutics

Shiv Kapoor Joins the Board of Directors at Microvascular Therapeutics

Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, Arizona, announced the appointment of Shiv Kapoor to the MVT Board of Directors. Mr. Kapoor will bring extensive experience in corporate strategy and financing from both biotechnology and finance... - February 03, 2022 - Microvascular Therapeutics

NuvOx to Present at Various Bio Forums in JPM Week

NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in... - January 14, 2022 - NuvOx Pharma

Mirror Biologics Announces Appointment of Dr. David Fineberg as Chief Medical Officer

Mirror Biologics Announces Appointment of Dr. David Fineberg as Chief Medical Officer

Mirror Biologics, Inc., a clinical stage immunotherapy company specializing in the development, manufacturing, commercialization and clinical translation of next generation immunomodulatory and therapeutic in-situ vaccines for cancer and infectious diseases, today announced the appointment of David... - December 26, 2021 - Mirror Biologics, Inc.

Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President

Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President

Global Regenerative Academy, independent subsidiary of the Global Regenerative Group Inc., has new board leadership. GRA President is now Prof. Tahsin Beyzadeoglu as announced during the opening Ceremony of GRC Dubai 2021 (November 19-21, 2021) by Mr. Mihail Blagoev (GRG Inc. VP) after being elected by the Scientific Board. - December 21, 2021 - Global Regenerative Academy

Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round

This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022. - December 09, 2021 - Mirror Biologics, Inc.

Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201

Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function,... - November 29, 2021 - Parvus Therapeutics U.S., Inc.

Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles

Today Parvus announced it has entered into an agreement with Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), for process development, scale-up and GMP manufacturing of NavacimTM nanoparticles, a key building block for all of our Navacim platform drug development candidates. - November 19, 2021 - Parvus Therapeutics U.S., Inc.

CANNA/Hemp Extraction Labs USA Announces Joint Venture Partnerships for Cannabis Cultivators/Growers and Cannapreneurs

CANNA/Hemp Extraction Labs USA (CHELUSA) announced today they are offering to finance and commission Cannabis Extraction Labs and Cannabis Cloning Labs in NM, NJ, AZ, IL, MT and VA. CHELUSA is looking to form strategic partnerships with Cultivators/Growers and Cannapreneurs in these key states. The... - November 18, 2021 - Hemp Extraction Labs USA

Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease

Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease

Mirror Biologics, Inc., a private clinical stage biopharmaceutical company, today announces the issuance of US Patent No. 11,160,852, “Method of Vaccinating Using Allogeneic Cells,” covering methods for creating a next generation of therapeutic vaccines against cancers and infectious... - November 17, 2021 - Mirror Biologics, Inc.

Pascal Biosciences Announces Financing

Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV: PAS) (OTC: PSCBF) (FSE: 6PB-FF) is pleased to announce a non-brokered private placement financing of up to 9,000,000 units (each a “Unit”) of securities at a price of $0.10 per Unit for aggregate gross proceeds of up to $900,000.00 (the “Offering”). - October 29, 2021 - Pascal Biosciences

OmeCare and Hillsborough City School District Renew Partnership for Student and Faculty COVID-19 PCR Testing

Partnership helps district ensure safety standards and meet COVID-19 testing protocols for the 2021-2022 school year. - October 16, 2021 - OmeCare

NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke

NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) under award number R41NS124450. STTR programs are highly competitive programs that... - October 12, 2021 - NuvOx Pharma

OmeCare and LifeSite Announce COVID-19 Testing Solution Partnership

The partnership provides a turnkey approach for workplaces, schools, major conventions and other group events looking to ensure safety and meet governmental mandates for students, staff, employees and event participants. - October 01, 2021 - OmeCare

Cayman Chemical Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration

The National Institute of Dental and Craniofacial Research has awarded Cayman Chemical with a $1,700,500 grant to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage... - September 19, 2021 - Cayman Chemical Company

AdvantaPure(R) Announces Fall Trade Show Appearances - Includes Events in the Northeast U.S.

AdvantaPure, the high purity division of NewAge Industries, will exhibit its silicone and TPE tubing and molded assemblies at the ISPE Boston Show, BioProcess International 2021, and Interphex, all taking place in September and October. AdvantaPure will also highlight its recent clean room expansion and its in-process building renovation at the events. The company is increasing its tubing manufacturing capacity to help meet demand for its Single-Use products. - September 16, 2021 - AdvantaPure

Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer

Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer

Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccine immunotherapy for cancer and infectious diseases where... - September 10, 2021 - Mirror Biologics, Inc.

NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts the Efficacy of Immunotherapy in a Mouse Model of Triple Negative Breast Cancer

NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of... - September 09, 2021 - NuvOx Pharma

Foxx Life Sciences Celebrates Major Expansion

Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India. The new locations add four additional SUT (Single Use Technologies) Cleanrooms that will allow Foxx to meet the high demands of their biotechnology and biopharmaceutical customers. New... - August 04, 2021 - Foxx Life Sciences

Mirror Biologics Announces Appointment of Global CRO Parexel to Provide Regulatory & Access Consulting Services

Mirror Biologics Announces Appointment of Global CRO Parexel to Provide Regulatory & Access Consulting Services

Mirror Biologics, Inc, (“Mirror” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases, where the active ingredients... - August 02, 2021 - Mirror Biologics, Inc.

NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM in Ischemic Stroke

NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. Stroke affects nearly 800,000 patients each year in the US. It is the fourth leading cause of death in this... - July 29, 2021 - NuvOx Pharma

NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer Utilizing Lead Drug Candidate NanO2TM

NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing... - July 23, 2021 - NuvOx Pharma

Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)

Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021 - Microvascular Therapeutics

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old

Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases where the active... - July 14, 2021 - Mirror Biologics, Inc.

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer

Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer

Mirror Biologics, Inc. (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which the active ingredients are living... - July 09, 2021 - Mirror Biologics, Inc.

Parvus Therapeutics Announces CEO, Senior Executive, and Board of Directors Appointments

Appoints CEO, Senior Executive, and Board of Directors: Peter M. Strumph, Chief Executive Officer; Brendan Classon PhD, Executive Vice President, Research and Development; Louis Demers, Vice President of Technical Operations; Matthew J. Hogan, member of the Board of Directors - July 06, 2021 - Parvus Therapeutics U.S., Inc.

GRG Announces 2021 Regenerative Medicine Congress in Dubai UAE

GRG Announces 2021 Regenerative Medicine Congress in Dubai UAE

The 2nd Global Regenerative Medicine Congress will be held in Dubai 9-11 September 2021. Registration is now open. Global Regenerative Academy is a world-renowned medical society scientifically studying the clinical application of biological products in the human body. Regenerative Medicine treatments using biological products have been used to slow down the natural aging process, treat a variety of pathologies and improve the quality of life of patients. - June 28, 2021 - Global Regenerative Academy

Paras Biopharmaceuticals Finland Oy Named as One of the Top Pharma Outsourcing Companies in Europe 2021

Paras Biopharmaceuticals Finland Oy Named as One of the Top Pharma Outsourcing Companies in Europe 2021

Paras Biopharmaceuticals Highlights Company Innovations that Decode and Create Biologics Medicines for Unmet Medical Needs (Pharma Tech Outlook, USA) - June 22, 2021 - Paras Biopharmaceuticals Finland Oy

Canada’s Leader in Cannabis Genetics Enters Medical Market

Canada’s Leader in Cannabis Genetics Enters Medical Market

Apollo Green, Canada’s leader in cannabis genetics, announced its entry into the medical marijuana sales with unique strains of cannabis not commonly available in the Canadian marketplace. The importance of having available alternatives for pain management cannot be understated. Studies have recently shown the link between cannabis availability and reduced use of opioids. Three specialty strains of plants and seven strains of seeds will be available in Ontario, Canada. - June 08, 2021 - Apollo Green

Updated Findings of COVID-19 Impact on Biopharmaceutical Industry & CRO Outsourcing Report

2021 Survey Quantifies Current and Expected impact of COVID-19 on Clinical Development and CRO Outsourcing and Changes Since 2020 - May 25, 2021 - Life Science Strategy Group, LLC

Advanced Silicon Group Closes Seed Preferred Equity Offering and Adds Alan Watson and Sarah Kelly to Board

Advanced Silicon Group, Inc. (ASG), a pioneer in silicon nanotechnology focused on developing novel biosensors, announced today the closing of a $1,020,000 seed preferred stock offering led by Cherrystone Angel Group with participation by MIT Alumni Angels of Northern California, Sidecar Angels and other private investors and the addition of two new Directors, Alan Watson, PhD, MBA and Sarah Kelly, PhD to its Board of Directors. - May 16, 2021 - Advanced Silicon Group

Cayman Develops Powerful, New Multiplex ELISA for Autoantibody Detection

Cayman Chemical's new Q-Plex™ Autoantibody Detection 10-Plex Panel, developed in collaboration with Quansys Biosciences, offers standardized, multiplex capabilities for the concurrent analysis of ten prominent analytes associated with rheumatoid arthritis or other autoimmune diseases. This... - May 16, 2021 - Cayman Chemical Company

CNS Healthcare Announces Launch of eReg Platform, Making Access to Regulatory Documents Available from Virtually Anywhere at Any Time

CNS Healthcare announced today the launch of eReg, an electronic regulatory binder platform. This first of its kind, web-based application will essentially replace paper binders and allow for remote monitoring capability. The proprietary platform developed by CNS Healthcare CIO & CISO, Florin... - May 14, 2021 - CNS Healthcare

Press Releases 1 - 50 of 1,234